Evidence Based Medicine on FHIR Implementation Guide, published by HL7 International / Clinical Decision Support. This guide is not an authorized publication; it is the continuous build for version 1.0.0-ballot built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/HL7/ebm/ and changes regularly. See the Directory of published versions

• Narrative Content
• XML
• JSON
• TTL

: SystematicReviewIncludedStudies: ADT and Docetaxel vs. ADT alone for metastatic hormone-naive prostate cancer - XML Representation

Raw xml | Download

<Library xmlns="http://hl7.org/fhir">
  <id value="179618"/>
  <meta>
    <versionId value="3"/>
    <lastUpdated value="2023-11-26T21:01:14.757Z"/>
    <profile
             value="http://hl7.org/fhir/uv/ebm/StructureDefinition/systematic-review-included-studies"/>
  </meta>
  <text>
    <status value="generated"/>
    <div xmlns="http://www.w3.org/1999/xhtml"><h2>Participants</h2><table class="grid"><tr><td>Author</td><td>Brian S. Alper</td></tr></table><h2>Related Artifacts</h2><table class="grid"><tr><td>derived-from</td><td/></tr><tr><td>contains</td><td/></tr><tr><td>contains</td><td/></tr><tr><td>contains</td><td/></tr></table><h2>Contents</h2></div>
  </text>
  <url value="https://fevir.net/resources/Library/179618"/>
  <identifier>
    <type>
      <coding>
        <system value="http://terminology.hl7.org/CodeSystem/v2-0203"/>
        <code value="ACSN"/>
        <display value="Accession ID"/>
      </coding>
      <text value="FEvIR Object Identifier"/>
    </type>
    <system value="https://fevir.net"/>
    <value value="179618"/>
    <assigner>
      <display value="Computable Publishing LLC"/>
    </assigner>
  </identifier>
  <version value="1.0.0-ballot"/>
  <title
         value="SystematicReviewIncludedStudies: ADT and Docetaxel vs. ADT alone for metastatic hormone-naive prostate cancer"/>
  <status value="active"/>
  <type>
    <coding>
      <system value="http://terminology.hl7.org/CodeSystem/library-type"/>
      <code value="asset-collection"/>
      <display value="Asset Collection"/>
    </coding>
  </type>
  <subjectReference>🔗 
    <reference value="Group/179619"/>
    <type value="Group"/>
    <display
             value="SystematicReviewEligibilityCriteria: ADT and Docetaxel vs. ADT alone for metastatic hormone-naive prostate cancer"/>
  </subjectReference>
  <date value="2023-11-26T18:15:27.442Z"/>
  <publisher value="HL7 International / Clinical Decision Support"/>
  <contact>
    <name value="HL7 International / Clinical Decision Support"/>
    <telecom>
      <system value="url"/>
      <value value="http://www.hl7.org/Special/committees/dss"/>
    </telecom>
  </contact>
  <description value="3 included studies"/>
  <useContext>
    <code>
      <system value="https://fevir.net/resources/CodeSystem/179423"/>
      <code value="evidence-communication"/>
      <display value="Evidence Communication"/>
    </code>
    <valueCodeableConcept>
      <coding>
        <system value="https://fevir.net/resources/CodeSystem/179423"/>
        <code value="SystematicReviewIncludedStudies"/>
        <display value="SystematicReviewIncludedStudies"/>
      </coding>
    </valueCodeableConcept>
  </useContext>
  <jurisdiction>
    <coding>
      <system value="http://unstats.un.org/unsd/methods/m49/m49.htm"/>
      <code value="001"/>
      <display value="World"/>
    </coding>
  </jurisdiction>
  <copyright value="https://creativecommons.org/licenses/by-nc-sa/4.0/"/>
  <author>
    <name value="Brian S. Alper"/>
  </author>
  <relatedArtifact>
    <type value="derived-from"/>
    <resourceReference>🔗 
      <reference value="Citation/179613"/>
      <type value="Citation"/>
      <display
               value="27308831 Efficacy and Safety of Combined Androgen Deprivation Therapy (ADT) and Docetaxel Compared with ADT Alone for Metastatic Hormone-Naive Prostate Cancer: A Systematic Review and Meta-Analysis."/>
    </resourceReference>
  </relatedArtifact>
  <relatedArtifact>
    <type value="contains"/>
    <resourceReference>🔗 
      <reference value="Citation/179615"/>
      <type value="Citation"/>
      <display
               value="23306100 Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial."/>
    </resourceReference>
  </relatedArtifact>
  <relatedArtifact>
    <type value="contains"/>
    <resourceReference>🔗 
      <reference value="Citation/179617"/>
      <type value="Citation"/>
      <display
               value="25301760 Survival with Newly Diagnosed Metastatic Prostate Cancer in the 'Docetaxel Era': Data from 917 Patients in the Control Arm of the STAMPEDE Trial (MRC PR08, CRUK/06/019)."/>
    </resourceReference>
  </relatedArtifact>
  <relatedArtifact>
    <type value="contains"/>
    <resourceReference>🔗 
      <reference value="Citation/179616"/>
      <type value="Citation"/>
      <display
               value="26244877 Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer."/>
    </resourceReference>
  </relatedArtifact>
</Library>